Courtney M.W. Tygesson

Cooley advised AIRO Group Holdings, a company specializing in advanced aerospace and defense technologies, on its $69 million initial public offering (IPO).

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its up to $75 million debt financing. Partner Addison Pierce led the Cooley team, which included Courtney Tygesson, Madison Jones, Margaret Barreto and Katie Lapidus.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.